CD109在肿瘤中作用与机制的研究进展

Advances in the Study of CD109 in Tumors

摘要: CD109是一种糖基磷脂酰肌醇(glycosylphosphatidylinositol, GPI)相关的细胞表面抗原，属于含α2巨球蛋白/C3、C4和C5超家族的复合物，被认为是TGF-β/Smads途径的一种新型受体。CD109在肿瘤进展中起重要调控作用，但在人体不同癌细胞中的表达和功能存在差异性。CD109作为细胞膜蛋白，可以被特异性抗体或者酶直接标记，也可能被药物输送的定向载体识别，有望成为有效的诊断性分子标志物和药理学治疗靶点。本文就CD109基本结构，在不同肿瘤中的表达差异及调控机制，以及CD109在临床诊断、预后和治疗中的临床应用潜力等方面进行阐述。

Abstract: CD109 is a glycosylphosphatidylinositol (GPI)-associated cell surface antigen that belongs to the α2-macroglobulin/C3, C4 and C5-containing superfamily and is thought to be a novel receptor for the TGF-β/Smads pathway. CD109 plays an important regulatory role in tumour progression, but is differentially expressed and functions in different human cancer cells. As a cell membrane protein, CD109 can be directly labeled by specific antibodies or enzymes, and may be recognized by targeted carriers for drug delivery, promising to be an effective diagnostic molecular marker and pharmacological therapeutic target. This paper addresses the basic structure of CD109, the differences in expression and regulatory mechanisms in different tumours, and the potential of CD109 for clinical applications in clinical diagnosis, prognosis and therapy.